Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Big 3 PBMs reaped $7.3B from generic specialty drug markups: FTC
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.
FTC says ‘Big 3 PBMs’ marked up generic drugs by thousands of percent
The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which it says focuses on
PBMs made more than $7B marking up specialty generics: FTC
The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty generic drugs for cancer and other conditions.
FTC finds top 3 PBMs inflated drug prices by $7.3B
The three PBMs inflated the drug prices dispensed at their affiliated pharmacies by hundreds and thousands of percent passing costs onto patients, employers and healthcare plans, according to a Jan. 14 news release from the agency.
FTC finds PBMs excessively marked up prices on specialty drugs
A new report issued by the Federal Trade Commission has found that prescription benefit manager units owned by CVS Health (NYSE:CVS), Cigna (CI) and UnitedHealth Group (UNH) significantly marked up prices for many specialty generic drugs over a six-year period.
21h
on MSN
UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%
CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...
23h
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
penncapital-star
10h
Regulator accuses drug middlemen of wild price hikes, possibly steering business to themselves
The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...
Hosted on MSN
1h
UnitedHealth Is Price Gouging Cancer Patients by Overcharging 'Thousands of Percent' for Live-Saving Meds, Pocketing Extra Billions: Feds
The UnitedHealth Group is overcharging patients for necessary life-saving drugs as a result of price gouging that increases ...
Healthcare Dive
7d
CVS successfully converts commercial pharmacy contracts to “cost plus” model
CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...
MinnPost
21h
FTC says Minnesota-based Optum, et al., inflate cancer drug prices 1,000%
Optum RX, CVS Caremark and Express Scripts are marking up drugs that treat cancer and multiple sclerosis by more than ...
9d
Zydus announces agreement with CVS Caremark
Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...
9d
Zydus Lifesciences rises 5% on signing agreement with CVS Caremark; Details
CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...
money.rediff
9d
Zydus Lifesciences Partners with CVS Caremark for Diabetes Drugs
Zydus Lifesciences has partnered with CVS Caremark to add its diabetes medications, Zituvio, Zituvimet, and Zituvimet XR, to ...
1d
Bernstein Sticks to Their Hold Rating for CVS Health (CVS)
Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...
MedCity News
9h
Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
UnitedHealth Group
Cigna
Federal Trade Commission
drug middlemen
PBM
Feedback